Can a booster shot supercharge CAR T-Cells against lymphoma?
NCT ID NCT07052305
First seen Jan 04, 2026 · Last updated May 01, 2026 · Updated 15 times
Summary
This early-phase study tests whether a drug called NT-I7 (a long-acting form of a natural immune protein) can safely boost the activity of CAR T-cells in people with relapsed or refractory large B-cell lymphoma. About 24 participants will receive NT-I7 after standard CAR T-cell therapy. The goal is to see if this combination helps the immune cells survive longer and fight the cancer more effectively.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.